Supernus v. MSN Pharmaceuticals: Qelbree ANDA Litigation Consolidated in D.N.J.
Supernus Pharmaceuticals filed suit against MSN Pharmaceuticals in the District of New Jersey, asserting six Orange Book-listed patents covering its Qelbree (viloxazine extended-release capsules) ADHD drug product. Within 165 days, the court consolidated this action with more than a dozen parallel ANDA cases into a single coordinated pretrial proceeding.
Multi-front ANDA battle over Qelbree viloxazine patents consolidated in NJ
Supernus Pharmaceuticals, Inc. — the NDA holder for Qelbree (viloxazine hydrochloride extended-release capsules, 100 mg, 150 mg, and 200 mg) — filed suit against MSN Pharmaceuticals, Inc. on July 11, 2025 in the U.S. District Court for the District of New Jersey, alleging infringement of six patents listed in the FDA Orange Book for Qelbree. The asserted patents span formulation, composition, and method-of-use claims tied to viloxazine ER technology.
At an Initial Scheduling Conference on December 17, 2025, the court directed all parties across the related Qelbree ANDA actions — involving at least fourteen defendants including Appco Pharma, Apotex, Aurobindo, Zydus, Macleods, Biophore, Zenara, Creckwood, and MSN — to submit a proposed Consolidation Order. The parties agreed, and the case was consolidated for pretrial purposes effective December 23, 2025, with proceedings governed by the schedule established in the lead action, Civil Action No. 25-12183.
The 165-day timeline to consolidation is consistent with courts managing complex, multi-filer ANDA waves efficiently. The public record does not disclose any claim construction positions, invalidity contentions, or settlement discussions at this stage. The substantive merits — including validity and non-infringement challenges to all six asserted patents — remain fully open and will be litigated in the consolidated proceeding, suggesting a protracted pretrial schedule ahead.
Filing to Case Consolidated in 165 days
165 days from filing to consolidation — typical for early-stage ANDA multi-defendant consolidation
What case consolidation means for the Qelbree ANDA litigation
Consolidation joins parallel cases, not a merits decision
Under Fed. R. Civ. P. 42(a), a court may consolidate actions sharing common questions of law or fact. Here, the court ordered consolidation for pretrial purposes, meaning MSN and all other Qelbree ANDA defendants will litigate on a unified schedule. No claims have been adjudicated, dismissed, or settled. The MSN docket (2:25-cv-13204) is administratively closed in favour of the lead case.
Procedural — no merits rulingSupernus gains litigation efficiency across 14+ defendants
Consolidation benefits Supernus by synchronising discovery, claim construction, and trial scheduling across all generic challengers simultaneously. This prevents individual defendants from exploiting staggered timelines and forces all ANDA filers to coordinate their invalidity and non-infringement positions. Supernus retains all six patent assertions and continues to pursue injunctive relief under Hatch-Waxman.
Plaintiff position preservedMSN now litigates on shared schedule with 13 co-defendants
MSN Pharmaceuticals must now coordinate with other ANDA filers — including larger generics such as Aurobindo, Apotex, and Zydus — within a single pretrial framework. Consolidation can create strategic tensions between co-defendants with differing invalidity theories or commercial timelines. MSN’s ability to pursue an independent litigation strategy is constrained by the unified schedule.
Coordinated defence requiredSix-patent Orange Book fortress signals prolonged exclusivity defence
With six Orange Book patents asserted and 14+ ANDA challengers consolidated, the Qelbree litigation reflects a layered IP strategy typical of high-revenue branded CNS drugs. The 30-month stay under Hatch-Waxman is likely in effect for early filers, meaning generic entry for viloxazine ER remains blocked pending resolution. R&D teams developing ADHD formulations should monitor claim construction outcomes closely.
Generic entry delayedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Supernus Pharmaceuticals, Inc. | Company | Specialty CNS pharmaceutical company — holder of US12121523B2 and five further Qelbree patentsSearch in Eureka ↗ |
| Defendant | Msn Pharmaceuticals, Inc. | Company | Generic pharmaceutical manufacturer filing ANDA for viloxazine extended-release capsulesSearch in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | EDGAR H. HAUG | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | JONATHAN HERSTOFF | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | KAITLIN M. FARRELL | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | NICHOLAS F. GIOVE | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Richard Frank Kurz | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | COUNSEL NOT ADMITTED TO USDC – NJ BAR | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Haug Partners, LLP | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing, LLP | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | CATHERINE SALERNO | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Gregory D. Miller | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Timothy P. Gonzalez | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Rivkin Radler, LLP | Law Firm | Representing Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order is procedural in nature and carries no substantive legal weight on the merits. The court’s directive to unify all Qelbree ANDA actions under a single pretrial schedule reflects judicial economy principles rather than any assessment of patent validity or infringement. All six asserted patents remain live, all defendants retain their defences, and the Hatch-Waxman 30-month stay framework continues to govern commercial entry timelines. The critical legal contests — claim construction, invalidity, and non-infringement — are yet to be scheduled.
US12121523B2 and five further Orange Book patents — Qelbree viloxazine ER technology
The six asserted patents — US12121523B2, US11324753B2, US9358204B2, US11458143B2, US9603853B2, and US9662338B2 — cover a range of intellectual property protecting Qelbree (viloxazine hydrochloride extended-release capsules). The application dates span from 2013 (US13/761757) to 2022 (US17/896774), reflecting a multi-generational filing strategy. The patents collectively protect formulation parameters, release profiles, and therapeutic use claims for viloxazine ER in the treatment of ADHD.
Viloxazine was originally developed as an antidepressant in Europe but was repurposed and reformulated by Supernus as an ER product for paediatric and adult ADHD, receiving FDA approval in 2021 as Qelbree. The six-patent Orange Book cluster is strategically significant: it forces comprehensive paragraph IV certifications from any ANDA filer and creates layered validity exposure. Competitors developing non-stimulant ADHD formulations or extended-release CNS products should conduct thorough FTO analysis against each individual patent claim scope.
Should you run an FTO against the six Qelbree Orange Book patents?
Any company developing viloxazine-containing products, non-stimulant ADHD extended-release formulations, or functionally similar CNS delivery systems should assess freedom to operate against all six asserted patents. The patents cover not only the specific Qelbree formulation but also broader ER capsule compositions and methods of use — claims that could read on alternative dosage forms or novel ADHD therapeutics in development. This is especially relevant for ANDA filers, 505(b)(2) applicants, and innovators in the non-stimulant ADHD space.
PatSnap Eureka’s FTO Search Agent can map your product’s technical features against the claim scope of each of the six Qelbree patents, identify prosecution history estoppel, and flag prior art that co-defendants may be relying on in the consolidated litigation. With 14+ challengers actively contesting these patents, the public record will soon contain rich invalidity contentions — Eureka can help you monitor and leverage that intelligence in real time.
Run a freedom-to-operate analysis on US12121523B2 to assess your product’s exposure
Run FTO in Eureka →Related Hatch-Waxman ANDA cases: viloxazine and CNS extended-release litigation
Explore parallel and precedent ANDA patent cases in the District of New Jersey involving CNS extended-release formulations and Orange Book-listed pharmaceutical patents.
What this case signals for the CNS/ADHD pharmaceutical IP landscape
Supernus’s six-patent Orange Book listing and coordinated enforcement against 14+ generics reflects a high-stakes exclusivity defence strategy in the ADHD drug market.
Multi-patent Orange Book listings create compounding litigation leverage
Listing six patents in the Orange Book for a single drug product forces each ANDA filer to certify against every listed patent, triggering multiple infringement actions. This stacks 30-month stays and multiplies the litigation cost burden on generics — a deliberate strategy to extend effective market exclusivity beyond base patent expiry.
Consolidation accelerates pretrial but does not resolve substantive risk
While consolidation is administratively efficient, it does not resolve any patent validity or infringement question. Brand holders and generic challengers alike should expect a full Hatch-Waxman trial schedule — including Markman hearings and expert discovery — before any commercial certainty on viloxazine ER generic entry emerges.
Supernus v Msn — key questions answered
The case was consolidated with related Qelbree ANDA actions on December 23, 2025, approximately 165 days after filing. At an Initial Scheduling Conference on December 17, 2025, the New Jersey District Court directed all defendants across the parallel Qelbree ANDA actions to submit a Consolidation Order. No merits ruling, settlement, or dismissal occurred; all six patents remain asserted.
Supernus asserted six Orange Book-listed patents: US12121523B2, US11324753B2, US9358204B2, US11458143B2, US9603853B2, and US9662338B2. These patents cover formulation, composition, and method-of-use aspects of Qelbree (viloxazine hydrochloride extended-release capsules, 100 mg, 150 mg, 200 mg) for ADHD treatment.
Consolidation under Fed. R. Civ. P. 42(a) merges the MSN action with more than a dozen parallel ANDA cases for pretrial purposes. All defendants — including Aurobindo, Apotex, Zydus, Macleods, and others — will litigate on a unified schedule. It is an administrative order; no patent claims have been adjudicated, and generic entry remains blocked by the Hatch-Waxman 30-month stay framework.
The Consolidation Order names at least 14 defendants: Appco Pharma LLC, Somerset Therapeutics LLC, Apotex Inc., Aurobindo Pharma Limited, Aurobindo Pharma U.S.A. Inc., Zydus Lifesciences Global FZE, Zydus Pharmaceuticals (USA) Inc., Zydus Lifesciences Limited, Creckwood Pharmaceuticals LLC, MSN Pharmaceuticals Inc., Zenara Pharma Private Limited, Biophore Pharma Inc., Macleods Pharmaceuticals Ltd., and Macleods Pharma USA Inc.
Qelbree (viloxazine hydrochloride ER) is a non-stimulant ADHD medication approved by the FDA in 2021 and marketed by Supernus. Its six-patent Orange Book listing creates a multi-layered IP barrier requiring ANDA challengers to certify against each patent individually, triggering separate 30-month stays and multiplying litigation costs — a strategy designed to extend effective market exclusivity beyond any single patent’s expiry.
PatSnap Eureka searches patents and litigation data to answer instantly.